Simon Brassel
Simon is a Health Economist and Electrical Engineer with over ten years of professional experience in international healthcare markets. His expertise covers the whole spectrum of health technologies, from pharmaceuticals to digital health technologies. He is especially passionate about promoting the broader value of vaccination, improving the value assessment of antimicrobials and gene therapies and exploring the interface of health economics and digital health.
Recently Simon worked amongst others on a novel method to assess the value of vaccines in freeing up resources in the healthcare system, an estimate of the global burden of C-19, a description of the Digital Health Landscape in England and an assessment of the impact on NICE’s decisions on international HTA agencies.
Publications and Insights
- Insight: Prevention pays off – so why aren’t we doing more of it?
- Publication: Analysing Global Immunisation Expenditure
- Insight: Around The World in HTAs: Thailand – An Ever-Evolving Policy Tool
- Publication: Socio-Economic Value of Adult Immunisation Programmes
- Publication: Developing a Conceptual Framework of Healthcare System Pressure
- Insight: Looking Further Afield – What Can Health Economics Learn from the Environmental Economics Approach to Discounting?
- Publication: Capturing the Broader Value of Antibiotics
- Publication: NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?
- Publication: Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechanism
- Insight: Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?
- Publication: Navigating the Landscape of Digital Health – United Kingdom
- Insight: The Economics of Antibiotics – Part 4: What Does the Antibiotics Market of the Future Look Like?
- Insight: The Economics of Antibiotics – Part 3: Creating a Healthy Global Market for New Antibiotics
- Insight: The Economics of Antibiotics – Part 2: Value Assessment within the NICE-NHS AMR Pilot
- Insight: The Economics of Antibiotics – Part 1: Why NICE and NHS England are Testing an Innovative HTA and Payment Model to Tackle Antimicrobial Resistance
- Publication: The Value of Vaccines in Maintaining Health System Capacity in England
- Publication: Realising The Broader Value of Vaccines in the UK: Ready for Prime Time?
- Publication: The Broader Value of Vaccines: The Return on Investment From a Governmental Perspective
- Publication: Realising the Broader Value of Vaccines in the UK
- Publication: Delivering the 2.4 Percent: Unlocking UK Pharma R&D Investment through Evidence-Based Policies
- Publication: The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment